NMD; sub-lingual nitroglycerin

PreclinicalSmall molecule

NMD; sub-lingual nitroglycerin is one of 4 small molecule programs targeting Nitric Oxide. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nitric OxideActive, not recruiting

Nitric OxidePreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Nitric Oxide

#DrugCompanyPhaseTrials

Inomax

MMallinckrodt

Phase 2

13 2

Ino

UUniversity of Colorado, Denver

Preclinical

1 3

L-NAME

UUniversity of Georgia

Preclinical

1 4

NMD; sub-lingual nitroglycerin

AAugusta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/AActive, not recruiting

Nitric Oxide

NCT02115724

Clinical

Trials by Indication[1]

Nitric Oxide1 trial

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

Active, not recruiting·—·N/A·NCT02115724·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NMD; sub-lingual nitroglycerin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NMD; sub-lingual nitroglycerin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NMD; sub-lingual nitroglycerin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Augusta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAugusta University

NMD; sub-lingual nitroglycerin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Nitric Oxide1 trial

References

Drug Info

Quick Facts

Related News